Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490611 | 0.85 | ROCK2 (0.53) | ROCK2HPGDCYP3A4 | |
| SCHEMBL13963463 | 0.81 | HPGD (0.43) | ROCK2HPGDCYP3A4 | |
| SCHEMBL4056161 | 0.72 | PDE1B (0.39) | KDM4EKDM4AALDH1A1HPGDTSHR | |
| SCHEMBL4056155 | 0.72 | PDE1B (0.39) | KDM4EKDM4AALDH1A1HPGDTSHR | |
| SCHEMBL4051429 | 0.71 | HPGD (0.43) | ADORA2AKDM4EKDM4AALDH1A1HPGD | |
| SCHEMBL4050365 | 0.71 | HPGD (0.43) | ADORA2AKDM4EKDM4AALDH1A1HPGD | |
| SCHEMBL4050872 | 0.71 | HPGD (0.43) | ADORA2AKDM4EKDM4AALDH1A1HPGD | |
| SCHEMBL4000261 | 0.70 | ADORA3 (0.38) | ROCK2KDM4EKDM4AALDH1A1HPGD | |
| SCHEMBL14563447 | 0.69 | ALDH1A1 (0.47) | ALDH1A1HPGDTSHRNPSR1CYP3A4 | |
| SCHEMBL14408874 | 0.69 | KDM4E (0.47) | KDM4EALDH1A1HPGDTSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476743-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1558588-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060189671-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-08-24 | — | — | US | disclosed |
| EP-1558588-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004032840-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189671-A1 | Compounds, compositions, and methods | TK1, TK2, TYMP | ROCK2 2250/4885CNR1 4070/4885ADORA2A 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.